Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 8, Number 11—November 2002
Tuberculosis Genotyping

Tuberculosis Genotyping Network, United States

Estimated Costs of False Laboratory Diagnoses of Tuberculosis in Three Patients

Jill M. Northrup*Comments to Author , Ann C. Miller*, Edward Nardell*†, Sharon Sharnprapai*, Sue Etkind*, Jeffrey Driscoll‡, Michael McGarry‡, Harry W. Taber‡, Paul Elvin*, Noreen L. Qualls§, and Christopher R. Braden§
Author affiliations: *Massachusetts Department of Public Health, Boston, Massachusetts, USA; †Harvard Medical School, Boston, Massachusetts, USA; ‡New York State Department of Health, Wadsworth Center, Albany, New York, USA; §Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 1

Cost inventory for three patients who received misdiagnoses of active tuberculosis disease on the basis of laboratory cross-contamination of Mycobacterium tuberculosis specimensa

Patient Public sectorb Private sectorc
Direct medical costs
TB medications Outpatient visits
TB medications and PPD
DOT provision
Tests and procedures
Contact investigations
Hospitalizations Outpatient visits
TB medications and PPD
          Tests and procedures
Contact investigations
          Direct nonmedical costs
Case managementd

aTB, tuberculosis; PPD, purified protein derivative of tuberculin; DOT, directly observed therapy.
bLocal and state public health departments, public health hospital and laboratory, and county and state correctional facilities.
cPrivate physicians, hospitals, and laboratories.
dHealth department case management and administrative support.
eOverhead costs, including rent, utilities, and supplies.

Main Article